| Host: |
Goat |
| Applications: |
Pep-ELISA/IHC |
| Reactivity: |
Human/Mouse/Rat/Cow |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-HMHA1 (57-71) is suitable for use in ELISA and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
IHC-5µg/mlELISA-antibody detection limit dilution 1:128000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
ARHGAP45 |
| Gene ID: |
23526 |
| Uniprot ID: |
HMHA1_HUMAN |
| Immunogen Region: |
57-71 |
| Accession Number: |
NP_036424.2 |
| Specificity: |
To avoid confusion please note that this antibody is designed to recognise the whole protein as coded by NP_036424.2 and won t recognise the peptide found eluted from HLA-A*0201 molecules by den Haan et al (Science. 1998 Feb 13;279 (5353) :1054-7, PM |
| Immunogen Sequence: |
KATGTLKRPTSLSRH |
| Function | Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL. |
| Protein Name | Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1Mhag Ha-1 |
| Database Links | Reactome: R-HSA-6798695Reactome: R-HSA-8980692Reactome: R-HSA-9013148Reactome: R-HSA-9013149 |
| Cellular Localisation | CytoplasmCell ProjectionRuffle Membrane |
| Alternative Antibody Names | Anti-Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1 antibodyAnti-Mhag Ha-1 antibodyAnti-ARHGAP45 antibodyAnti-HMHA1 antibodyAnti-KIAA0223 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
